A humanoid robot works on a factory line, showcasing advanced automation in real-world production. PHOTO: AGIBOT
Robots that learn on the job: AgiBot tests reinforcement learning in real-world manufacturing.
Updated
November 27, 2025 3:26 PM
A humanoid robot works on a factory line, showcasing advanced automation in real-world production. PHOTO: AGIBOT
Shanghai-based robotics firm AgiBot has taken a major step toward bringing artificial intelligence into real manufacturing. The company announced that its Real-World Reinforcement Learning (RW-RL) system has been successfully deployed on a pilot production line run in partnership with Longcheer Technology. It marks one of the first real applications of reinforcement learning in industrial robotics.
The project represents a key shift in factory automation. For years, precision manufacturing has relied on rigid setups: robots that need custom fixtures, intricate programming and long calibration cycles. Even newer systems combining vision and force control often struggle with slow deployment and complex maintenance. AgiBot’s system aims to change that by letting robots learn and adapt on the job, reducing the need for extensive tuning or manual reconfiguration.
The RW-RL setup allows a robot to pick up new tasks within minutes rather than weeks. Once trained, the system can automatically adjust to variations, such as changes in part placement or size tolerance, maintaining steady performance throughout long operations. When production lines switch models or products, only minor hardware tweaks are needed. This flexibility could significantly cut downtime and setup costs in industries where rapid product turnover is common.
The system’s main strengths lie in faster deployment, high adaptability and easier reconfiguration. In practice, robots can be retrained quickly for new tasks without needing new fixtures or tools — a long-standing obstacle in consumer electronics production. The platform also works reliably across different factory layouts, showing potential for broader use in complex or varied manufacturing environments.
Beyond its technical claims, the milestone demonstrates a deeper convergence between algorithmic intelligence and mechanical motion.Instead of being tested only in the lab, AgiBot’s system was tried in real factory settings, showing it can perform reliably outside research conditions.
This progress builds on years of reinforcement learning research, which has gradually pushed AI toward greater stability and real-world usability. AgiBot’s Chief Scientist Dr. Jianlan Luo and his team have been at the forefront of that effort, refining algorithms capable of reliable performance on physical machines. Their work now underpins a production-ready platform that blends adaptive learning with precision motion control — turning what was once a research goal into a working industrial solution.
Looking forward, the two companies plan to extend the approach to other manufacturing areas, including consumer electronics and automotive components. They also aim to develop modular robot systems that can integrate smoothly with existing production setups.
Keep Reading
A closer look at how machine intelligence is helping doctors see cancer in an entirely new light.
Updated
November 28, 2025 4:18 PM
Serratia marcescens colonies on BTB agar medium. PHOTO: UNSPLASH
Artificial intelligence is beginning to change how scientists understand cancer at the cellular level. In a new collaboration, Bio-Techne Corporation, a global life sciences tools provider, and Nucleai, an AI company specializing in spatial biology for precision medicine, have unveiled data from the SECOMBIT clinical trial that could reshape how doctors predict cancer treatment outcomes. The results, presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlight how AI-powered analysis of tumor environments can reveal which patients are more likely to benefit from specific therapies.
Led in collaboration with Professor Paolo Ascierto of the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, the study explores how spatial biology — the science of mapping where and how cells interact within tissue — can uncover subtle immune behaviors linked to survival in melanoma patients.
Using Bio-Techne’s COMET platform and a 28-plex multiplex immunofluorescence panel, researchers analyzed 42 pre-treatment biopsies from patients with metastatic melanoma, an advanced stage of skin cancer. Nucleai’s multimodal AI platform integrated these imaging results with pathology and clinical data to trace patterns of immune cell interactions inside tumors.
The findings revealed that therapy sequencing significantly influences immune activity and patient outcomes. Patients who received targeted therapy followed by immunotherapy showed stronger immune activation, marked by higher levels of PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells. Those who began with immunotherapy benefited most when PD-1+ CD8 T-cells engaged closely with PD-L1+ CD4 T-cells along the tumor’s invasive edge. Meanwhile, in patients alternating between targeted and immune treatments, beneficial antigen-presenting cell (APC) and T-cell interactions appeared near tumor margins, whereas macrophage activity in the outer tumor environment pointed to poorer prognosis.
“This study exemplifies how our innovative spatial imaging and analysis workflow can be applied broadly to clinical research to ultimately transform clinical decision-making in immuno-oncology”, said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne.
The collaboration between the two companies underscores how AI and high-plex imaging together can help decode complex biological systems. As Avi Veidman, CEO of Nucleai, explained, “Our multimodal spatial operating system enables integration of high-plex imaging, data and clinical information to identify predictive biomarkers in clinical settings. This collaboration shows how precision medicine products can become more accurate, explainable and differentiated when powered by high-plex spatial proteomics – not limited by low-plex or H&E data alone”.
Dr. Ascierto described the SECOMBIT trial as “a milestone in demonstrating the possible predictive power of spatial biomarkers in patients enrolled in a clinical study”.
The study’s broader message is clear: understanding where immune cells are and how they interact inside a tumor could become just as important as knowing what they are. As AI continues to map these microscopic landscapes, oncology may move closer to genuinely personalized treatment — one patient, and one immune network, at a time.